Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects With Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)
Brief Summary: The purpose of this extension trial was to further evaluate the safety and tolerability of oral cladribine in subjects who have previously completed treatment within Trial 25643 (CLARITY). This trial also explored clinical benefit of prolonged 192-week versus 96-week treatment.


Options:
A: Arm Label: Cladribine Low/Placebo (LLPP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cladribine High Dose/Placebo (HLPP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cladribine Low/Low Dose (LLLL); Type: EXPERIMENTAL; Interventions: Drug: Cladribine | Arm Label: Cladribine High/Low Dose (HLLL); Type: EXPERIMENTAL; Interventions: Drug: Cladribine | Arm Label: Placebo/Cladribine Low Dose (PPLL); Type: EXPERIMENTAL; Interventions: Drug: Cladribine | Arm Label: Placebo/No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cladribine 3.5 mg/kg/No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cladribine 5.25 mg/kg/No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Cladribine; Assigned to Arm(s): Cladribine Low/Low Dose (LLLL) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cladribine Low/Placebo (LLPP) | Intervention Type: DRUG; Name: Cladribine; Assigned to Arm(s): Cladribine High/Low Dose (HLLL) | Intervention Type: DRUG; Name: Cladribine; Assigned to Arm(s): Placebo/Cladribine Low Dose (PPLL) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cladribine High Dose/Placebo (HLPP)
B: Arm Label: FTY720D 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FTY720D 1.25 mg switch to 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720D 0.5 mg, FTY720D 1.25 mg switch to 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Arm Label: Peginterferon Beta-1a Q2W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a) | Arm Label: Peginterferon Beta-1a Q4W; Type: EXPERIMENTAL; Interventions: Drug: BIIB017 (peginterferon beta-1a), Drug: Placebo | Intervention Type: DRUG; Name: BIIB017 (peginterferon beta-1a); Assigned to Arm(s): Peginterferon Beta-1a Q2W, Peginterferon Beta-1a Q4W, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Peginterferon Beta-1a Q4W, Placebo
D: Arm Label: Placebo-Controlled Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo-Controlled Phase: Laquinimod 0.6 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod, Drug: Placebo | Arm Label: Placebo-Controlled Phase: Laquinimod 1.2 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Active Treatment Phase: Laquinimod 0.6 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod, Drug: Placebo | Arm Label: Active Treatment Phase: Laquinimod 1.2 mg; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Active Treatment Phase: Off Drug; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Laquinimod; Assigned to Arm(s): Active Treatment Phase: Laquinimod 0.6 mg, Active Treatment Phase: Laquinimod 1.2 mg, Placebo-Controlled Phase: Laquinimod 0.6 mg, Placebo-Controlled Phase: Laquinimod 1.2 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Active Treatment Phase: Laquinimod 0.6 mg, Placebo-Controlled Phase: Laquinimod 0.6 mg, Placebo-Controlled Phase: Placebo

Answer: A